Skip to main content

Muscular Dystrophy and cannabis in Maryland

The state does not list this condition by name, but its statute or regulator permits a certifying physician to add conditions case-by-case. Patients should expect to bring full diagnostic records to the certification visit.

Physician-discretion program
✗ No
LEGAL
30-day supply as certif…
POSSESSION
$25/yr
STATE FEE
7–21 d
TIMELINE
Physician-discretion program. The state does not list this condition by name, but its statute or regulator permits a certifying physician to add conditions case-by-case. Patients should expect to bring full diagnostic records to the certification visit.

Maryland statute and program

The Maryland Medical Cannabis Program is the operating authority for Maryland patient certification. The authoritative legal text is: Md. Code, Alcoholic Beverages and Cannabis Article: Title 36.

What the evidence says about cannabis and Muscular Dystrophy

Muscular dystrophy refers to a group of more than 30 inherited genetic disorders characterized by progressive muscle weakness and degeneration caused by mutations in genes encoding proteins that maintain muscle-fiber integrity. The major clinical subtypes include:

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Muscular Dystrophy page.

How to qualify in Maryland

The Maryland Medical Cannabis Program requires the following registration steps for a Muscular Dystrophy patient (or any qualifying diagnosis):

  1. Register as a patient with the Maryland Cannabis Administration (MCA). Patients self-register through the MCA online patient portal before seeing a provider. Registration requires a Maryland driver license or state ID, a passport-style photograph, and proof of Maryland residency. Out-of-state patients with a qualifying condition may also register and are issued a 30-day temporary identification card.
  2. Get certified by an MCA-registered provider. A Maryland-licensed physician, dentist, podiatrist, advanced practice registered nurse, nurse midwife, or physician assistant registered with the MCA must issue a written certification documenting a qualifying condition such as chronic pain, severe nausea, seizures, glaucoma, PTSD, or another condition the provider determines may benefit from medical cannabis. Telehealth certifications are accepted.
  3. Pay the $25 patient registration fee. The MCA patient identification card fee is $25 for a three-year registration (reduced from the original $50 under 2024 Maryland Cannabis Administration reforms). Caregiver registration is $50 per caregiver. Renewals require updated provider certification at the end of the three-year period.
  4. Purchase from licensed Maryland dispensaries. With the MCA registration ID, patients may purchase from any licensed Maryland medical-cannabis dispensary up to a 30-day supply (defined by potency-adjusted dosage units rather than weight). Adult-use retail launched July 1, 2023; patients retain medical-only product access, lower taxation, and statutory employment and family-court protections under the Maryland Medical Cannabis Act.
State registration fee
$25
Physician visit (typical)
$125–$250
Certification to card
7–21 days
Out-of-state patients
Eligible
Minors
Eligible with caregiver

For full Maryland registration steps, fees, and reciprocity rules, see the Maryland cannabis-laws page.

ICD-10 code

A certifying physician documenting Muscular Dystrophy for the Maryland medical cannabis program will typically record ICD-10 G71.0 or SNOMED-CT 76670001 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Maryland list Muscular Dystrophy as a qualifying condition for medical cannabis?

Not by name, but Maryland permits physician discretion. Under Maryland Medical Cannabis Program, a certifying physician can add a condition like Muscular Dystrophy on a case-by-case basis when the physician judges that the patient would benefit from medical cannabis. This is different from a state where the qualifying-condition list is fixed in statute. Whether a particular physician will certify Muscular Dystrophy depends on the physician's training, the strength of the patient's documentation, and the practitioner's reading of the available evidence — evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). Patients should expect to bring full diagnostic records to the certification visit.

How do I get a Maryland medical marijuana card for Muscular Dystrophy?

Step one is finding a physician licensed in Maryland who is registered with Maryland Medical Cannabis Program and willing to evaluate Muscular Dystrophy cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Maryland does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. Confirm the current process with the state regulator before applying, because the rules change.

What does the evidence say about cannabis for Muscular Dystrophy?

For Muscular Dystrophy, evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Muscular Dystrophy lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Muscular Dystrophy should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Muscular Dystrophy and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Muscular Dystrophy; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. Maryland Constitution Article XX: Adult-Use Cannabis (Question 4 of 2022)accessed May 15, 2026
  2. Md. Code, Alcoholic Beverages and Cannabis Article: Title 36accessed May 15, 2026
  3. Maryland Cannabis Administrationaccessed May 15, 2026
  4. NIH National Institute of Neurological Disorders and Stroke: Muscular Dystrophyaccessed May 18, 2026
  5. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 18, 2026

    “Substantial evidence that oral cannabinoids are effective antiemetics in the treatment of chemotherapy-induced nausea.”

  6. Muscular Dystrophy Association: About Neuromuscular Diseasesaccessed May 18, 2026
  7. MedlinePlus: Muscular dystrophyaccessed May 18, 2026
  8. FDA: Epidiolex (cannabidiol) prescribing informationaccessed May 18, 2026